Clinical Trial Update: Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate SAR445877 in combination with FOLFOX6 and bevacizumab as first-line therapy for microsatellite-stable metastatic colorectal cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• SAR445877 (SAR445877)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 1, SAR445877 | Phase 1 | Status: NOT_YET_RECRUITING